Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patricia Gerber

Allergy & Immunology North Charleston, SC Medical Doctor

NPI 1023097532 CMS profile 136808

7555 Northside Dr, North Charleston, SC 29420

Open in the dashboard

General payments

$16,688

520 records reported · program years 2019–2025

Research payments

$591

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$953,263 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patricia Gerber of North Charleston, SC is reported in the CMS Open Payments database as having received $16,688 across 520 general payments and $591 in research payments paid to them. Separately, studies naming them as principal investigator received $953,263 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,839 104
2024 General $2,520 76
2023 General $1,996 69
2023 Research $591 6
2022 General $1,958 72
2021 General $1,712 65
2020 General $1,012 54
2019 General $4,652 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Gerber
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Patricia Gerber were reported at $2,839. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Patricia Gerber Allergy & Immunology median Middle half National median
2019 $4,652 $594 $163–$1,512 $163
2020 $1,012 $426 $106–$1,233 $114
2021 $1,712 $638 $157–$1,708 $132
2022 $1,958 $790 $205–$1,961 $149
2023 $1,996 $852 $220–$2,147 $160
2024 $2,520 $865 $203–$2,267 $164
2025 $2,839 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioCryst Pharmaceuticals, Inc. $3,009 9 payments
  2. Genzyme Corporation $2,410 74 payments
  3. CSL Behring $1,831 93 payments
  4. AstraZeneca Pharmaceuticals LP $1,596 58 payments
  5. Pfizer Inc. $1,219 60 payments
  6. GlaxoSmithKline, LLC. $1,099 41 payments
  7. Regeneron Healthcare Solutions, Inc. $672 15 payments
  8. Genentech USA, Inc. $581 21 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $513 20 payments
  10. Amgen Inc. $468 18 payments
  11. Other $3,291 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,549 509 payments
  2. Honoraria $2,100 1 payment
  3. Travel and Lodging $665 3 payments
  4. Education $374 7 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $4,032 128 payments
  2. Haegarda $959 51 payments
  3. CUTAQUIG $941 48 payments
  4. PANZYGA $864 43 payments
  5. TEZSPIRE Respiratory $620 14 payments
  6. Xolair $557 20 payments
  7. DUPIXENT Inflammation And Immunology $555 12 payments
  8. Hizentra $554 25 payments
  9. Orladeyo $455 14 payments
  10. TEZSPIRE Inflammation $415 16 payments
  11. Other $6,373 257 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $591 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

662

Median for Allergy/ Immunology: 449

Drug cost

$265,761

Median for Allergy/ Immunology: $169,700

Branded share of claims

42.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 35 $152,979
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 86 $61,256
Spiriva Respimat Tiotropium Bromide Brand 14 $10,964
Advair Hfa Fluticasone Propion/Salmeterol Brand 22 $8,484
Epinephrine Generic 43 $6,962
Breo Ellipta Fluticasone/Vilanterol Brand 17 $5,956
Arnuity Ellipta Fluticasone Furoate Brand 20 $4,960
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 17 $2,723
Zafirlukast Generic 33 $2,299
Fluticasone Propionate Hfa Fluticasone Propionate Brand 14 $2,120

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$127,923

Of which drugs: $69,079

Medicare patients

215

Average age 72

Services billed

6,717

152 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 51%
Diabetes 27%
Osteoporosis 25%
Chronic kidney disease 20%
Depression 18%
COPD 17%
Ischemic heart disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 13 1,920 $57,108

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$845 35 —
AREXVY
$217 — —
CUTAQUIG
$199 — —
TEZSPIRE
$164 — —
XOLAIR
$115 — 1,920

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

526 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record